These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Chen SF; Wang H; Huang YM; Li ZY; Wang SX; Yu F; Zhao MH; Chen M Clin J Am Soc Nephrol; 2015 May; 10(5):750-8. PubMed ID: 25749534 [TBL] [Abstract][Full Text] [Related]
25. Effects of cyclophosphamide on the prognosis of Japanese patients with renal vasculitis associated with anti-neutrophil cytoplasmic antibody-positive microscopic polyangiitis. Iwabuchi M; Nakaya I; Tsuchiya Y; Shibagaki Y; Yamaguchi T; Fukuhara S; Oe Y; Sakuma T; Sato T; Taguma Y; Soma J Clin Exp Nephrol; 2016 Oct; 20(5):712-719. PubMed ID: 26590052 [TBL] [Abstract][Full Text] [Related]
26. Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis. Yoo J; Jung SM; Song JJ; Park YB; Lee SW Clin Rheumatol; 2018 Aug; 37(8):2133-2141. PubMed ID: 29557539 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA; Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823 [TBL] [Abstract][Full Text] [Related]
28. Systemic immune-inflammation index could estimate the cross-sectional high activity and the poor outcomes in immunosuppressive drug-naïve patients with antineutrophil cytoplasmic antibody-associated vasculitis. Kim Y; Choi H; Jung SM; Song JJ; Park YB; Lee SW Nephrology (Carlton); 2019 Jul; 24(7):711-717. PubMed ID: 30203901 [TBL] [Abstract][Full Text] [Related]
29. Low sensitivity of total lymphocyte count as a surrogate marker to identify antepartum and postpartum Indian women who require antiretroviral therapy. Gupta A; Gupte N; Bhosale R; Kakrani A; Kulkarni V; Nayak U; Thakar M; Sastry J; Bollinger RC; J Acquir Immune Defic Syndr; 2007 Nov; 46(3):338-42. PubMed ID: 17846559 [TBL] [Abstract][Full Text] [Related]
30. ANCA-associated vasculitis: a comparison of cases presenting to nephrology and rheumatology services. McNicholas BA; Griffin TP; Donnellan S; Ryan L; Garrahy A; Coughlan R; Giblin L; Lappin D; Reddan D; Carey JJ; Griffin MD QJM; 2016 Dec; 109(12):803-809. PubMed ID: 27318367 [TBL] [Abstract][Full Text] [Related]
31. Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients. van der Ryst E; Kotze M; Joubert G; Steyn M; Pieters H; van der Westhuizen M; van Staden M; Venter C J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):238-44. PubMed ID: 9803965 [TBL] [Abstract][Full Text] [Related]
32. Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody associated vasculitis: A retrospective cohort study. Hessels AC; Rutgers A; Sanders JSF; Stegeman CA PLoS One; 2018; 13(4):e0195524. PubMed ID: 29630648 [TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes in elderly patients with ANCA-associated vasculitis. McGovern D; Williams SP; Parsons K; Farrah TE; Gallacher PJ; Miller-Hodges E; Kluth DC; Hunter RW; Dhaun N Rheumatology (Oxford); 2020 May; 59(5):1076-1083. PubMed ID: 31794032 [TBL] [Abstract][Full Text] [Related]
36. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Karras A; Pagnoux C; Haubitz M; Groot K; Puechal X; Tervaert JWC; Segelmark M; Guillevin L; Jayne D; Ann Rheum Dis; 2017 Oct; 76(10):1662-1668. PubMed ID: 28546260 [TBL] [Abstract][Full Text] [Related]
37. Infectious profile in inpatients with ANCA-associated vasculitis: a single-center retrospective study from Southern China. Lao M; Huang M; Li C; Li H; Qiu Q; Zhan Z; Chen D Clin Rheumatol; 2020 Feb; 39(2):499-507. PubMed ID: 31576488 [TBL] [Abstract][Full Text] [Related]
38. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L; Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500 [TBL] [Abstract][Full Text] [Related]
39. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR; N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198 [TBL] [Abstract][Full Text] [Related]
40. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR; Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]